Contact
searchSearch
HMP Global
Login

Lymphoma (ASH) Basic Listing

Updates in Lymphoma
From the ASH Annual Meeting & Exposition

Sairah Ahmed, MD
Conference Coverage
Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL
12/07/2025
Sairah Ahmed, MD
For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.
For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.
For patients with at least 3...
12/07/2025
Oncology
Elizabeth Budde, MD, PhD
Conference Coverage
BAFFR CAR T-Cell Therapy Shows Durable Responses, Manageable Toxicity for Patients With B-Cell Lymphomas Relapsing After or Ineligible for CD19-Targeted Treatments
12/07/2025
Elizabeth Budde, MD, PhD
Elizabeth Budde, MD, PhD, shares data on PMB-CT01, a novel autologous CAR-T cell therapy developed against B-cell activating factor for patients with B-cell lymphomas relapsing after or ineligible for CD-19 targeted treatments at the 2025 ASH...
Elizabeth Budde, MD, PhD, shares data on PMB-CT01, a novel autologous CAR-T cell therapy developed against B-cell activating factor for patients with B-cell lymphomas relapsing after or ineligible for CD-19 targeted treatments at the 2025 ASH...
Elizabeth Budde, MD, PhD, shares...
12/07/2025
Oncology
Christina Poh, MD
Videos
Tafasitamab Added to Lenalidomide and Ritixumab Shows Benefit for Patients With R/R FL
01/15/2025
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to...
01/15/2025
Oncology
Elizabeth Brem, MD, University of California, Irvine
Videos
Odronextamab Monotherapy vs Standard of Care Therapy for Follicular Lymphoma: OLYMPIA-1 Trial
12/16/2024
Elizabeth Brem, MD, discusses safety and preliminary efficacy results from the phase 3 OLYMPIA-1 trial exploring odronextamab monotherapy for patients with high-risk follicular lymphoma.
Elizabeth Brem, MD, discusses safety and preliminary efficacy results from the phase 3 OLYMPIA-1 trial exploring odronextamab monotherapy for patients with high-risk follicular lymphoma.
Elizabeth Brem, MD, discusses...
12/16/2024
Oncology
John Burke, MD
Conference Coverage
First-Line Subcutaneous Mosunetuzumab Shows Encouraging Efficacy, Manageable Safety for Patients With Low Tumor Burden Follicular Lymphoma
12/13/2024
John M. Burke, MD
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results...
12/13/2024
Oncology
Anne Marijn Kramer, MD, PhD
Videos
CD22-Directed CAR-T Therapy Demonstrates Durable Remissions for Patients With Large B-Cell Lymphomas Relapsing After CD19-Directed CAR-T Therapy
12/08/2024
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after...
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after...
Anne Marijn Kramer, MD, PhD,...
12/08/2024
Oncology
Tycel Phillips, MD
Conference Coverage
Analyzing Response Rate and Line of Therapy Correlation Among Patients With R/R Follicular Lymphoma
12/10/2023
Tycel Phillips
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Conference Coverage
Epcoritamab Plus Rituximab and Lenalidomide Yields High Complete Metabolic Response Rate in Follicular Lymphoma
12/16/2022
Janelle Bradley
In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.
In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.
In patients with relapsed or...
12/16/2022
Oncology
Conference Coverage
Epcoritamab With Rituximab Plus Lenalidomide Demonstrates Promising Efficacy as First-Line Therapy for Patients With Follicular Lymphoma
12/16/2022
Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Epcoritamab combined with...
12/16/2022
Oncology
Conference Coverage
Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine for Treatment of Patients With R/R Follicular Lymphoma
12/16/2022
Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.
Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.
Usage of regimens of...
12/16/2022
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use